Ane C.F. Nunes

Prof. Dr. Ane C.F. Nunes

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in Journal of Cardiac Failure
Verified
Journal Article
Closed access
YSYasunori Suematsu
Yasunori Suematsu
WJWanghui Jing
Wanghui Jing
ANAne C.F. Nunes
Ane C.F. Nunes
MKMoti L. Kashyap
Moti L. Kashyap
MKMahyar Khazaeli
Mahyar Khazaeli
HMHamid Moradi
Hamid Moradi

4 May 2019 in Translational Stroke Research
Verified
Journal Article
Open access
PDF file
WLWei Ling Lau
Wei Ling Lau
ANAne C.F. Nunes
Ane C.F. Nunes
VVVitaly Vasilevko
Vitaly Vasilevko
DFDavid Floriolli
David Floriolli
LLLong Lertpanit
Long Lertpanit
MFMark Fisher
Mark Fisher
Brain microbleeds are increased in chronic kidney disease (CKD) and their presence increases risk of cognitive decline and stroke. We examined the interaction between CKD and brain microhemorrhages (the neuropathological substrate of microbleeds) in mouse and cell culture models and studied progression of microbleed burden on serial brain imaging from humans. Mouse studies: Two CKD models were investigated: adenine-induced tubulointerstitial nephritis and surgical 5/6 nephrectomy. Cell culture studies: bEnd.3 mouse brain endothelial cells were grown to confluence, and monolayer integrity was measured after exposure to 5–15% human uremic serum or increasing concentrations of urea. Human studies: Progression of brain microbleeds was evaluated on serial MRI from control, pre-dialysis CKD, and dialysis patients. Microhemorrhages were increased 2–2.5-fold in mice with CKD independent of higher blood pressure in the 5/6 nephrectomy model. IgG staining was increased in CKD animals, consistent with increased blood–brain barrier permeability. Incubation of bEnd.3 cells with uremic serum or elevated urea produced a dose-dependent drop in trans-endothelial electrical resistance. Elevated urea induced actin cytoskeleton derangements and decreased claudin-5 expression. In human subjects, prevalence of microbleeds was 50% in both CKD cohorts compared with 10% in age-matched controls. More patients in the dialysis cohort had increased microbleeds on follow-up MRI after 1.5 years. CKD disrupts the blood–brain barrier and increases brain microhemorrhages in mice and microbleeds in humans. Elevated urea alters the actin cytoskeleton and tight junction proteins in cultured endothelial cells, suggesting that these mechanisms explain (at least in part) the microhemorrhages and microbleeds observed in the animal and human studies.

20 February 2017 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
YCYongen Chang
Yongen Chang
WLWei Ling Lau
Wei Ling Lau
HJHyunil Jo
Hyunil Jo
KTKazuyuki Tsujino
Kazuyuki Tsujino
LGLeslie Gewin
Leslie Gewin
DSDean Sheppard
Dean Sheppard
Activated fibroblasts are deemed the main executors of organ fibrosis. However, regulation of the pathologic functions of these cells in vivo is poorly understood. PDGF receptor β (PDGFRβ) is highly expressed in activated pericytes, a main source of fibroblasts. Studies using a PDGFRβ promoter–driven Cre system to delete αv integrins in activated fibroblasts identified these integrins as core regulators of fibroblast activity across solid organs, including the kidneys. Here, we used the same PDGFRβ-Cre line to isolate and study renal fibroblasts ex vivo. We found that renal fibroblasts express three αv integrins, namely αvβ1, αvβ3, and αvβ5. Blockade of αvβ1 prevented direct binding of fibroblasts to the latency-associated peptide of TGF-β1 and prevented activation of the latent TGF-β complex. Continuous administration of a recently described potent small molecule inhibitor of αvβ1, compound 8, starting the day of unilateral ureteral obstruction operation, inhibited collagen deposition in the kidneys of mice 14 days later. Compound 8 also effectively attenuated renal failure, as measured by BUN levels in mice fed an adenine diet known to cause renal injury followed by fibrosis. Inhibition of αvβ1 integrin could thus hold promise as a therapeutic intervention in CKD characterized by renal fibrosis.

1 March 2008 in Hypertension
Verified
Journal Article
Closed access
PDF file
TPTiago Veiga Pereira
Tiago Veiga Pereira
ANAne C.F. Nunes
Ane C.F. Nunes
MRMartina Rudnicki
Martina Rudnicki
YYYoshiji Yamada
Yoshiji Yamada
APAlexandre Costa Pereira
Alexandre Costa Pereira
JKJose Krieger
Jose Krieger
Angiotensinogen (AGT) gene polymorphisms have been linked to increased risk of hypertension, but the data remain controversial. In this study we review the most commonly investigated polymorphisms at the AGT locus (other than M235T) and provide summary estimates regarding their association with essential hypertension, while addressing heterogeneity, as well as publication biases. Data on 26 818 subjects from 46 studies for the 4 most-studied AGT variants (T174M in exon 2 and 3 promoter variants: A-6G, A-20C, and G-217A) were meta-analyzed. Statistically significant associations with hypertension were identified for the T174M (odds ratio [OR]: 1.19; 95% CI: 1.07 to 1.33; P =0.002) and G-217A (OR: 1.37; 95% CI: 1.17 to 1.59; P =0.00006) polymorphisms. A dual but consistent effect was observed for the −20C allele, which was associated with a decreased risk of hypertension in populations of mixed and European ancestries (OR: 0.64; 95% CI: 0.44 to 0.92; P =0.02 and OR: 0.77; 95% CI: 0.65 to 0.91; P =0.003, respectively), but with a 24% increase in the odds of hypertension in Asian subjects (OR: 1.24; 95% CI: 1.04 to 1.48; P =0.02). No association of the A-6G variant with hypertension was detected. Current studies support the notion that single variants at the AGT might modulate the risk of hypertension but indicate caution in interpreting these results because of the putative presence of publication bias and gene-environment interactions.

15 December 2017
Verified
Journal Article
Closed access
WJWanghui Jing
Wanghui Jing
NVNosratola Vaziri
Nosratola Vaziri
ANAne C.F. Nunes
Ane C.F. Nunes
YSYasunori Suematsu
Yasunori Suematsu
TFTed Farzaneh
Ted Farzaneh
HMHamid Moradi
Hamid Moradi

1 December 2018 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Open access
PDF file
WLWei Ling Lau
Wei Ling Lau
NVNosratola D. Vaziri
Nosratola D. Vaziri
ANAne C.F. Nunes
Ane C.F. Nunes
ACAndré M. Comeau
André M. Comeau
MLMorgan G.I. Langille
Morgan G.I. Langille
KWKatrine L. Whiteson
Katrine L. Whiteson
In chronic kidney disease (CKD), the gut microbiome is altered and bacterial-derived uremic toxins promote systemic inflammation and cardiovascular disease. Ferric citrate complex is a dietary phosphate binder prescribed in end-stage kidney disease patients to treat hyperphosphatemia and secondary hyperparathyroidism. Iron is an essential nutrient in both microbes and mammals. The present study was undertaken to test the hypothesis that the large iron load administered with ferric citrate in CKD may significantly change the gut microbiome. Male Sprague Dawley rats underwent 5/6 nephrectomy to induce CKD. Normal control and CKD rats were randomized to regular chow or a 4% ferric citrate diet for 6 weeks. Fecal and cecal microbial DNA was analyzed via 16S rRNA gene sequencing on the Illumina MiSeq. CKD rats had lower abundances of Firmicutes and Lactobacillus compared to normal rats and had lower overall gut microbial diversity. CKD rats treated with ferric citrate had improved hemoglobin and creatinine clearance, and amelioration of hyperphosphatemia and hypertension. Ferric citrate treatment increased bacterial diversity in CKD rats almost to levels observed in control rats. The tryptophanase-possessing families Verrucomicrobia, Clostridiaceae and Enterobacteriaceae were increased by ferric citrate treatment. The uremic toxins indoxyl sulfate and p-cresyl sulfate were not increased with ferric citrate treatment. Verrucomicrobia was largely represented by Akkermansia muciniphila which has important roles in mucin degradation and gut barrier integrity. In summary, ferric citrate therapy in CKD rats was associated with significant changes in the gut microbiome and beneficial kidney and blood pressure parameters.